Abstract
In a clinical study, BMY-28100, a new cephalosporin antibiotic, was administered orally to 13 patients with various dermatological infections, to evaluate its usefulness and safety.
1) In 13 patients (with folliculitis 3, furuncle or furunculosis 4, cellulitis 1, erysipelas 1 and superficial secondary infection 4) given BMY-28100, clinical efficacy was assessed as: 7 cured, 5 excellent and 1 good. The overall clinical efficacy of the drug was 100%.
2) Twelve bacterial strains isolated from cutaneous lesions were Staphylococcus aureus (7), coagulase-negative staphylococci (2), Streptococcus pyogenes (2), and Propianibacterium acnes (1). Although 2 strains of S. aureus were resistant, the other strains were sensitive to BMY-28100, and the elimination rate was 100%.
3) There were neither side-effects, nor abnormal laboratory data related to the treatment.
